We also suggest that healthcare providers get into consideration the minimal source of Wegovy® as portion of their determination-making when initiating new patients on therapy, recognizing the potential of disruption in treatment.At the moment, we don't endorse switching to Saxenda® (liraglutide) injection 3 mg to be a viable alternate procedur